Clinical Trial

Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The goal of this study is to compare the study drug, sacituzumab govitecan-hziy, versus doctors' treatment of choice in participants with HR+/HER2- metastatic breast cancer (MBC) who have failed at least 2 prior chemotherapy regimens.
Protocol Amendment History 13 amendments
This ClinicalTrials.gov record has been amended 13 times since 2020-11-17; most recent amendment 2026-02-05.
Status change: Recruiting → Active, Not Recruiting 2022-12-06
Status change: Not Yet Recruiting → Recruiting 2020-11-23
Trial Details
NCT Number NCT04639986
Lead Sponsor Gilead Sciences
Conditions Metastatic Breast Cancer
Enrollment 331 participants
Start Date 2020-11-23
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-02-09